Loading...
Please wait, while we are loading the content...
Similar Documents
Eradication of hepatitis C virus and non‐liver‐related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection
| Content Provider | Semantic Scholar |
|---|---|
| Author | Berenguer, Juan Castellano, Elena Rodríguez‐ Carrero, Ana Deixy Flores Wichmann, Miguel Angel Von Montero, Marta Barrientos Galindo, María Mallolas, Josép Crespo, Manuel Téllez, María J. Quereda, Carmen Sanz, José Barros, Carlos Augusto Silva Tural, Cristina Santos, Ignacio Pulido, Federido Guardiola, Josep María Rubio, Rafael Ortega, Enrique Montes, María Luisa Jusdado, Juan José Gaspar, Gabriel Esteban, Hermínia Bellón, José María García, Juan González‐ |
| Copyright Year | 2017 |
| Abstract | We assessed non-liver-related non-acquired immunodeficiency syndrome (AIDS)-related (NLR-NAR) events and mortality in a cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients treated with interferon (IFN) and ribavirin (RBV), between 2000 and 2008. The censoring date was May 31, 2014. Cox regression analysis was performed to assess the adjusted hazard rate (HR) of overall death in responders and nonresponders. Fine and Gray regression analysis was conducted to determine the adjusted subhazard rate (sHR) of NLR deaths and NLR-NAR events considering death as the competing risk. The NLR-NAR events analyzed included diabetes mellitus, chronic renal failure, cardiovascular events, NLR-NAR cancer, bone events, and non-AIDS-related infections. The variables for adjustment were age, sex, past AIDS, HIV transmission category, nadir CD4+ T-cell count, antiretroviral therapy, HIV RNA, liver fibrosis, HCV genotype, and exposure to specific anti-HIV drugs. Of the 1,625 patients included, 592 (36%) had a sustained viral response (SVR). After a median 5-year follow-up, SVR was found to be associated with a significant decrease in the hazard of diabetes mellitus (sHR, 0.57; 95% confidence interval [CI], 0.35-0.93; P = 0.024) and decline in the hazard of chronic renal failure close to the threshold of significance (sHR, 0.43; 95% CI, 0.17-1.09; P = 0.075). CONCLUSION Our data suggest that eradication of HCV in coinfected patients is associated not only with a reduction in the frequency of death, HIV progression, and liver-related events, but also with a reduced hazard of diabetes mellitus and possibly of chronic renal failure. These findings argue for the prescription of HCV therapy in coinfected patients regardless of fibrosis stage. (Hepatology 2017;66:344-356). |
| Starting Page | 344 |
| Ending Page | 356 |
| Page Count | 13 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.natap.org/2017/HCV/hep29071.pdf |
| PubMed reference number | 28109003v1 |
| Alternate Webpage(s) | https://doi.org/10.1002/hep.29071 |
| DOI | 10.1002/hep.29071 |
| Journal | Hepatology |
| Volume Number | 66 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Acquired Immunodeficiency Syndrome Antiretroviral therapy Bone Tissue Cell Count Cessation of life Chemical and Drug Induced Liver Injury Coinfection Confidence Intervals Diabetes Mellitus Fibrosis Fibrosis, Liver Genotyping Techniques HIV Infections Hepatitis A Hepatitis B Hepatitis C virus Hepatitis C, Chronic Immunologic Deficiency Syndromes Infection Kidney Failure, Chronic Leukemia, B-Cell NLR Proteins Non-Small Cell Lung Carcinoma Patients Regression Analysis Renal Insufficiency Ribavirin Total Peripheral Resistance |
| Content Type | Text |
| Resource Type | Article |
